34,767 results match your criteria Lymphoma Diffuse Large Cell


Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 Study.

JCO Glob Oncol 2020 Jul;6:1034-1040

AIDS Malignancy Consortium, New York, NY.

The purpose of this article is to describe lessons from the first lymphoma clinical trial conducted by the AIDS Malignancy Consortium (AMC) in sub-Saharan Africa (SSA). AMC-068 was a randomized phase II comparison of intravenous versus oral chemotherapy for HIV-positive diffuse large B-cell lymphoma. Opening in 2016, AMC-068 planned to enroll 90 patients (45 per arm) in Kenya, Malawi, Uganda, and Zimbabwe over 24 months and follow patients for 24 months to assess overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/GO.20.00152DOI Listing

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.

Cancer Med 2020 Jul 7. Epub 2020 Jul 7.

Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.

Our aim was to compare the efficacy and safety of two recently developed biosimilars of pegfilgrastim, a pegylated form of the recombinant human granulocyte-colony stimulating factor (G-CSF) analog filgrastim with those of the reference pegfilgrastim. We retrospectively analyzed data from patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who were treated with first-line R-CHOP chemotherapy and received pegylated G-CSF for primary prophylaxis. The following pegylated G-CSFs were analyzed in this study: reference pegfilgrastim (Neulasta ) and two of its biosimilars (tripegfilgrastim; Dulastin and pegteograstim; Neulapeg ). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3261DOI Listing

High Incidence of Antiphospholipid Antibodies in Newly Diagnosed Patients With Lymphoma and a Proposed aPL Predictive Score.

Clin Appl Thromb Hemost 2020 Jan-Dec;26:1076029620928392

Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Given that the presence of antiphospholipid (aPL) antibodies has been proposed to be associated with thrombosis in newly diagnosed patients with lymphoma, we conducted a prospective cohort study on these patients. In all, 154 patients were enrolled. More than half were advanced-stage diffuse large B-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1076029620928392DOI Listing

Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma.

Eur J Haematol 2020 Jul 6. Epub 2020 Jul 6.

Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Objectives: Testicular diffuse large B-cell lymphoma (T-DLBCL) is a rare and aggressive extranodal lymphoma. We have previously shown that high content of tumor-infiltrating lymphocytes (TILs) and PD-1 expressing TILs associate with better survival in T-DLBCL. In this study, we have further characterized distinct TIL subtypes and their proportions in association with patient demographics and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13484DOI Listing

Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [F] FDG PET/CT.

Eur J Nucl Med Mol Imaging 2020 Jul 6. Epub 2020 Jul 6.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian, Beijing, 100142, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-020-04946-0DOI Listing

YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma.

Signal Transduct Target Ther 2020 Jul 6;5(1):116. Epub 2020 Jul 6.

Hongqiao International Institute of Medicine, Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41392-020-00236-1DOI Listing

Follicular dendritic cell tumor in the context of a Castleman disease in a patient with Diffuse Large B Cell Lymphoma: Diagnosis and follow-up with F-FDG PET/CT.

Rev Esp Med Nucl Imagen Mol 2020 Jul 3. Epub 2020 Jul 3.

Servei Medicina Nuclear-IDI Girona. Hospital Universitari de Girona Dr. Josep Trueta, Catalunya, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.remn.2020.06.011DOI Listing

Prognostic significance of histologic grade and Ki-67 proliferation index in follicular lymphoma.

Hematol Oncol 2020 Jul 6. Epub 2020 Jul 6.

Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.

The prognostic value of histologic grading and the Ki-67 proliferation index in follicular lymphoma (FL) is controversial. This study investigated the clinical usefulness of these two factors in Asian FL patients. Four hundred and thirty-three patients diagnosed with FL were retrospectively reviewed with a median follow-up time of 47. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2778DOI Listing

Recent malignant testicular tumor trend in Japan, a country with an aging population: a large-scale study of 2012-2015 hospital-based cancer registry data.

Jpn J Clin Oncol 2020 Jul 6. Epub 2020 Jul 6.

Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Objective: Japan's national database of hospital-based cancer registries is estimated to cover ~67% of all new cancer cases. Using this database, we analyzed the characteristics of the recently diagnosed testicular malignancy.

Methods: We obtained data for 6510 adult testicular malignancy patients diagnosed in 2012-2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyaa110DOI Listing

Neurolymphomatosis, a rare manifestation of peripheral nerve involvement in lymphomas: suggestive features and diagnostic challenges.

J Peripher Nerv Syst 2020 Jul 5. Epub 2020 Jul 5.

Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy.

Background: Neurolymphomatosis, the infiltration of the peripheral nervous system from lymphoid cells, represents an uncommon manifestation of lymphomas. We describe the challenging diagnostic work-up in a patient with neurolymphomatosis.

Case Report: a 58-yr-old woman with previous breast diffuse large B-cell lymphoma (DLBCL) treated with chemo- and radiation-therapy, presented with dysesthesias, neuropathic pain at left abdomen and thigh, and weakness at left lower limb 9 years after disease remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jns.12401DOI Listing

Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.

Brain Tumor Pathol 2020 Jul 5. Epub 2020 Jul 5.

Department of Pathology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan.

In recent years, the features of lymphomas associated with chronic inflammation, referred to as diffuse large B-cell lymphoma (DLBCL) associated with chronic inflammation (DLBCL-CI), have been elucidated. DLBCL-CI is an aggressive lymphoma occurring in the context of long-standing chronic inflammation and showing an association with Epstein-Barr virus. Fibrin-associated diffuse large B-cell lymphoma (F-DLBCL) was suggested as a new and unusual form of DLBCL-CI in the most recent version of the World Health Organization classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-020-00373-zDOI Listing

Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells.

Int J Med Sci 2020 30;17(10):1375-1384. Epub 2020 May 30.

Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Cladribine is a purine nucleoside analog used to treat B-cell chronic lymphocytic leukemia and hairy cell leukemia, also functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. The therapeutic role of cladribine against diffuse large B-cell lymphoma cells (DLBCL) is still undefined. In the present study, we demonstrated that cladribine inhibited cell proliferation and induced G phase arrest in human DLBCL cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijms.41793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330656PMC

A case of primary cutaneous B-cell lymphoma with immature features in an old man. Diffuse Large B-cell Lymhpoma with immature features or B-cell Lymhpoblastic Lymphoma?

J Cutan Pathol 2020 Jul 4. Epub 2020 Jul 4.

Oncology and Hematology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Primary cutaneous B-cell lymphomas are a heterogeneous group of lymphoid neoplasms primarily occurring in the skin. Although most cases are represented by primary cutaneous follicle center cell lymphoma, primary cutaneous marginal zone lymphoma and leg-type diffuse large B-cell lymphoma, other diffuse large B-cell lymphomas and B-cell lymphoblastic lymphoma may rarely present primarily in the skin. In this setting, the presence of histopathologic and immunohistochemical features of cellular immaturity is exceedingly rare and may represent a diagnostic challenge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13795DOI Listing

FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.

Br J Haematol 2020 Jul 4. Epub 2020 Jul 4.

King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, UK.

The UK National Cancer Research Institute initiated a prospective study (UKCRN-ID 1760) to assess the prognostic value of early fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in diffuse large B-cell lymphoma (DLBCL). In total, 189 patients with DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) had baseline and post-cycle-2 PET (PET2) within a quality assurance framework. Treatment decisions were based on CT; PET2 was archived for central blinded reporting after treatment completion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16875DOI Listing

Diffuse large B-cell lymphoma in right atrium.

Eur Heart J 2020 Jul 4. Epub 2020 Jul 4.

Department of Cardiovascular Surgery, West China Hospital, Sichuan University, No. 37 GuoXue Xiang, Chengdu, Sichuan 610041, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehaa516DOI Listing

Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.

Mod Pathol 2020 Jul 3. Epub 2020 Jul 3.

Department of Hematopathology, Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.

Recently, comprehensive genomic analyses have allowed a better molecular characterization of diffuse large B-cell lymphoma (DLBCL), offering novel opportunities in patient risk stratification and management. In the era of precision medicine, this has allowed us to move closer toward a more promising therapeutic outcome in the setting of DLBCL. In this review, we highlight the newly reported heterogeneous mutational landscapes of DLBCL (from two whole-exome sequencing studies, and from a more recent work targeting a 293-gene of a hematologic malignancy-designed panel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-020-0616-yDOI Listing

Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.

Anticancer Res 2020 Jul;40(7):3781-3792

Department of Medicine, Clinic III, Hematology, Oncology and Palliative Medicine, University Medical Center Rostock, Rostock, Germany

Background/aim: Canine B-cell lymphoma represents a useful in vivo model for human diffuse large B-cell lymphoma (DLBCL). Pan-Bromodomain and extra-terminal (BET) inhibition targeting BRD2/3/4 and selective inhibition of BRD4, as well as spleen tyrosine kinase (SYK) inhibition, are currently evaluated as haematologic cancer therapy. Herein, we characterized the differences in the biologic response of isoform-specific or pan-BET inhibition alone or in combination with SYK inhibition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14367DOI Listing

Clinical utility of target capture-based panel sequencing in hematological malignancies: a multicenter feasibility study.

Cancer Sci 2020 Jul 3. Epub 2020 Jul 3.

Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Although next-generation sequencing-based panel testing is well-practiced in the field of cancer medicine for the identification of target molecules in solid tumors, the clinical utility and clinical issues surrounding panel testing in hematological malignancies have yet to be fully evaluated. We conducted a multicenter prospective clinical-sequencing study to verify the feasibility of a panel test for hematological tumors, including acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, and diffuse large B-cell lymphoma. Out of 96 eligible patients, 79 patients (82%) showed potentially actionable findings, based on the clinical-sequencing assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.14552DOI Listing

Correction to: Differential diagnosis of sinonasal extranodal NK/T cell lymphoma and diffuse large B cell lymphoma on MRI.

Neuroradiology 2020 Jul 2. Epub 2020 Jul 2.

Department of Radiology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.

The above article was published online with incorrect Fig. 1. The correct Fig. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00234-020-02488-8DOI Listing

Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Haematologica 2020 Jul 2. Epub 2020 Jul 2.

Hematopathology Section, Hospital Cllinic, University of Barcelona, Barcelona, Spain

Chronic lymphocytic leukemia is a well-defined lymphoid neoplasm with very heterogeneous biological and clinical behavior. The last decade has been remarkably fruitful in novel findings elucidating multiple aspects of the pathogenesis of the disease including mechanisms of genetic susceptibility, insights into the relevance of immunogenetic factors driving the disease, profiling of genomic alterations, epigenetic subtypes, global epigenomic tumor cell reprogramming, modulation of tumor cell and microenvironment interactions, and dynamics of clonal evolution from early steps in monoclonal B cell lymphocytosis to progression and transformation into diffuse large B-cell lymphoma. All this knowledge has offered new perspectives that are being exploited therapeutically with novel target agents and management strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.236000DOI Listing

Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma.

Cancer Discov 2020 Jul 2. Epub 2020 Jul 2.

British Columbia Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada.

Diffuse large B-cell lymphoma (DLBCL) represents a grouping of clinically and biologically heterogeneous tumors. Application of advanced molecular technology has significantly expanded our knowledge of DLBCL pathobiology, allowing identification of subgroups with common, potentially targetable, biological themes. Here, we review the recent molecular analyses that could provide a paradigm shift to a new taxonomy, foundational to the rational transition to precision medicine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0174DOI Listing

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.

Blood Adv 2020 Jul;4(13):3024-3033

Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In addition, CAR T-cell-mediated toxicities can involve any organ system, with varied impacts on outcomes, depending on patient factors and involved organs. We performed detailed analysis of organ-specific toxicities and their association with outcomes in 60 patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 CAR T cells by assessing all toxicities in organ-based groups during the first year posttreatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001972DOI Listing

Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.

Int J Hematol 2020 Jul 1. Epub 2020 Jul 1.

Department of Medicine and Biosystemic Science, Faculty of Medicine, Kyusyu University, Fukuoka, Japan.

Duvelisib is a novel dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ. This single-arm, multicenter phase I study investigated its safety, pharmacokinetics, and preliminary efficacy in Japanese patients with relapsed or refractory lymphoma. Duvelisib was administered orally twice daily at 25 mg in 28-day cycles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02929-3DOI Listing

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.

Ann Hematol 2020 Jul 1. Epub 2020 Jul 1.

Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.

High-grade B cell lymphomas with rearrangements on C-MYC and BCL2 and/or BCL6 (HGBL with MYC and BCL2 and/or Bcl6 rearrangement) are associated with worse clinical outcomes and thus were introduced as a separate new category in the recently updated WHO classification. From 2012 to 2016, we analyzed a consecutive cohort of large B cell lymphomas (LBCLs) for C-MYC, BCL2, and BCL6 rearrangements and correlated our results with clinical-pathological parameters. Ten of 78 (13%) cases had a C-MYC and BCL2 and/or BCL6 rearrangement, so-called double or triple hit (DH), while double/triple copy number gains (CNGs) were found in eight (10%) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04124-0DOI Listing

Primary extra nodal Non-Hodgkin's lymphoma of urinary bladder presenting as a bladder tumor: A case report.

Ann Med Surg (Lond) 2020 Aug 17;56:68-71. Epub 2020 Jun 17.

Deptt.of Pathology, PGIMS Rohtak, Haryana, India.

Introduction: Primary non-Hodgkin's lymphoma (NHL) of urinary bladder is an exceedingly rare entity accounting for 0.2% of the primary neoplastic lesions. This tumor has female predominance; with most of the cases seen in middle-aged females. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amsu.2020.05.045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322174PMC

Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma.

Cancer Manag Res 2020 25;12:5041-5048. Epub 2020 Jun 25.

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China.

Background: Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is a common subtype of extranodal non-Hodgkin lymphoma (NHL), with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) as the commonly used treatment regimen. However, full cycles of standard R-CHOP present the risk of severe bleeding or perforation, even leading to emergency surgery, especially for those with deep lesions in their first 1-2 cycles of treatment. This study aims to explore the safety and efficacy of fractioned R-CHOP (rituximab d0, 50% dose of CHOP d1 and d5) followed by standard R-CHOP cycles in PG-DLBCL patients guided by endoscopic ultrasonography (EUS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S260974DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323805PMC

PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.

Cancer Manag Res 2020 25;12:4999-5008. Epub 2020 Jun 25.

Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Laboratory of Digestive Oncology, Affiliated Cancer Hospital of Xiangya Medical School & Hunan Cancer Hospital, Central South University, Changsha, People's Republic of China.

Introduction: Primary gastric diffuse large B-cell lymphoma (GDLBCL) is a heterogeneous disease in clinicopathological features and prognosis. Programmed death ligand-1 (PD-L1) and microRNA-34a (miR-34a) play crucial roles in GDLBCL progress. The purpose of this research is to explore the clinical significance of PD-L1 and miR-34a expression in GDLBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S247874DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323802PMC

Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.

Leuk Lymphoma 2020 Jul 1:1-7. Epub 2020 Jul 1.

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

CAR T-cells have transformed the therapeutic landscape for patients with relapsed/refractory aggressive B-cell lymphomas. Currently, three CAR T-cell products are approved or soon to be approved: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. These products differ in construct, manufacturing, clinical trial design and toxicity profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1786563DOI Listing

Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen.

Leuk Lymphoma 2020 Jul 1:1-7. Epub 2020 Jul 1.

Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

It is unknown whether rituximab increases the risk of second primary malignancies (SPMs) in patients with diffuse large cell B-cell lymphoma (DLBCL). We assessed SPMs in DLBCL patients diagnosed between 1996 and 2014 in comparison with the general Israeli population and dependent on rituximab treatment. Jewish patients had no increased risk for SPMs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1779257DOI Listing

How disease stage impacts the rate of second primary malignancies in patients with diffuse large B-cell lymphoma.

Authors:
Manali Kamdar

Clin Adv Hematol Oncol 2020 Mar;18(3):147-149

Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, Colorado.

View Article

Download full-text PDF

Source

Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian, single-centre experience.

Intern Med J 2020 Jul 1. Epub 2020 Jul 1.

Department of Clinical Haematology, Monash Health, Melbourne, Australia.

Background: Histologic transformation (HT) is an important event with adverse prognosis in the natural history of indolent lymphomas. There is minimal data on HT in the Australian setting.

Aim: To characterise patients with biopsy-proven HT and their outcomes identified at a tertiary Australian Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.14965DOI Listing

Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.

Cancer Med 2020 Jul 1. Epub 2020 Jul 1.

Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Purpose: Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coadministration of anti-CD19 and anti-CD20 CAR-T cells treatment for R/R DLBCL and evaluated its efficacy and toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3259DOI Listing

Long-Term Observation of the Progression From Nodal Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma in a Dog.

Vet Pathol 2020 Jul 17;57(4):520-524. Epub 2020 Jun 17.

The University of Tokyo, Tokyo, Japan.

A 4-year and 10-month old female Pembroke Welsh Corgi presented with an enlarged right popliteal lymph node, and a histopathological diagnosis of nodal marginal zone lymphoma (nMZL) was made. After resection of the lymph node, follow-up observation was continued without chemotherapy. At 22 months after initial presentation, the dog developed enlargement of peripheral lymph nodes, and the histopathological diagnosis was late-stage nMZL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300985820932143DOI Listing

Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission.

Onco Targets Ther 2020 22;13:5879-5885. Epub 2020 Jun 22.

Department of Hematology, The Affiliated DrumTower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.

Purpose: To evaluate whether autologous cytokine-induced killer (CIK) cell immunotherapy improves the prognosis of patients with high-risk diffuse large B cell lymphoma (DLBCL) after the first complete remission (CR).

Patients And Methods: Peripheral blood mononuclear cells (PBMCs) were extracted from 20 patients with high-risk DLBCL (IPI≥3) after the first CR. Twenty CR patients who were age- and sex-matched during the same period were selected as controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S254291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319512PMC

Primary Pulmonary Diffuse Large B Cell Lymphoma Mimicking Metastasis: A Case Report and Literature Review.

Onco Targets Ther 2020 19;13:5837-5843. Epub 2020 Jun 19.

Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.

Primary pulmonary diffuse large B cell lymphoma (PPDLBCL) is extremely rare, with fewer than 40 cases reported to date and a lack of systemic analysis. Herein, we present a case of PPDLBCL mimicking metastasis in a heavily treated patient with breast cancer. To our knowledge, this is the first reported case of PPDLBCL in a patient with breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S251344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311097PMC

B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data.

Onco Targets Ther 2020 18;13:5795-5805. Epub 2020 Jun 18.

Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing 100191, People's Republic of China.

Purpose: B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively correlated with inferior clinical features. In non-Hodgkin lymphoma (NHL), however, the roles of B7-H6 and the underlying mechanism of action remain unclear. Through in vivo and in vitro experiments, the aim of this study was to explore the regulatory mechanism of B7-H6 in NHL in order to provide new therapeutic strategies that can potentially be applied in clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S257512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308182PMC

Long Noncoding RNA SNHG12 Indicates the Prognosis and Accelerates Tumorigenesis of Diffuse Large B-Cell Lymphoma Through Sponging microR-195.

Onco Targets Ther 2020 12;13:5563-5574. Epub 2020 Jun 12.

Department of Hematology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, People's Republic of China.

Background: Small nucleolar RNA host gene 12 (SNHG12) expression is associated with multiple cancers, including renal cell carcinoma, prostate cancer, cervical cancer, nasopharyngeal carcinoma, colorectal cancer, and hepatocellular carcinoma. However, SNHG12 biological function is unclear in diffuse large B-cell lymphoma (DLBCL).

Methods: SNHG12 expression and associated clinicopathological characteristics were evaluated in DLBCL tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S249429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305849PMC

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.

Onco Targets Ther 2020 8;13:5123-5133. Epub 2020 Jun 8.

Department of Internal Medicine, Division of Hematology, Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Abstract: Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL. This review article summarizes data from clinical trials of polatuzumab and discusses its current role and future directions in the treatment of patients with B-cell non-Hodgkin lymphoma.

Methods: We conducted a literature search in PubMed and Google Scholar from inception to January 2020, using the following terms: polatuzumab and CD79. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S219449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293382PMC

Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2.

Sci Rep 2020 Jun 30;10(1):10680. Epub 2020 Jun 30.

Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

BCL2 overexpression has been reported to be associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL). However, currently there is no consensus on the evaluation of BCL2 expression and only the proportion of BCL2 positive cells are evaluated for the determination of BCL2 positivity. This study aimed to define BCL2 positivity by quantitative analysis integrating both the intensity and proportion of BCL2 expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67738-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326926PMC

Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.

In Vivo 2020 Jul-Aug;34(4):2127-2134

Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, School of Medicine, Chonnam National University, Hwasun, Republic of Korea

Background/aim: The present study retrospectively investigated the predictive accuracy of interim positron emission tomography/computed tomography (iPET/CT) based on the Deauville 5-point scale (5-PS) and a quantitative SUV-based assessment in patients with extranodal (EN) diffuse large B cell lymphoma (DLBCL).

Patients And Methods: The Deauville 5-PS and the SUVmax reduction (ΔSUVmax) assessment for interpreting the response to iPET/CT were used.

Results: A total of 163 patients were enrolled in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/invivo.12018DOI Listing

Histopathological Features and Ann Arbor Stage in Periocular Lymphoma.

In Vivo 2020 Jul-Aug;34(4):1965-1974

Department of Ophthalmology, University Medical Center Rostock, Rostock, Germany

Background: To evaluate biodata, symptoms/signs, lymphoma type, localization, stage level, treatment choice and outcome of ocular adnexal lymphoma (OAL).

Patients And Methods: A single-center retrospective analysis of 56 patients with OAL was performed from 1998 to 2018.

Results: OAL involved the orbit in 44. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/invivo.11993DOI Listing

Influence of Rurality, Race, and Ethnicity on Non-Hodgkin Lymphoma Incidence.

Clin Lymphoma Myeloma Leuk 2020 May 16. Epub 2020 May 16.

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.

Introduction: Exposure to lymphomagens vary by geography. The extent to which these contribute to racial and ethnic disparities in non-Hodgkin lymphoma (NHL) incidence is not well understood. We sought to evaluate the association between urban-rural status and racial and ethnic disparities in the 3 major NHL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.010DOI Listing

Autoimmune/inflammatory syndrome induced by methylmethacrylate associated to seronegative antiphospholipid syndrome and diffuse large B-cell non-Hodgkin's lymphoma.

Lupus 2020 Jun 30:961203320936767. Epub 2020 Jun 30.

Division of Postgraduate Studies, Universidad Nacional Autónoma de México, México City, Mexico.

Background: Autoimmune/inflammatory syndrome induced by adjuvants has been associated with different substances used for cosmetic purposes; for example, silicone, methylmethacrylate, autoimmune disorders and cancer.

Discussion: A 40-year-old man with a prior history of methylmethacrylate injection in the buttocks for aesthetic purposes 8 years ago, presented with deep venous thrombosis in the left leg 6 months ago, accompanied with inflammation, hardening, changes in colour, ulceration in the buttocks, arthritis, myalgias and fever. Weak and moderate lupus anticoagulant and low levels of anticardiolipin antibodies were present. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320936767DOI Listing

Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965.

Cancers (Basel) 2020 Jun 26;12(6). Epub 2020 Jun 26.

Division of Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.

The monocarboxylate transporter 1 (MCT1) is a key element in tumor cell metabolism and inhibition of MCT1 with AZD3965 is undergoing clinical trials. We aimed to investigate nutrient fluxes associated with MCT1 inhibition by AZD3965 to identify possible biomarkers of drug action. We synthesized an F-labeled lactate analogue, [F]--fluorolactate ([F]--FL), that was used alongside [F]fluorodeoxyglucose ([F]FDG), and C-labeled glucose and lactate, to investigate the modulation of metabolism with AZD3965 in diffuse large B-cell lymphoma models in NOD/SCID mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061703DOI Listing

A Case of Primary Sacral Lymphoma Evaluated by 18F-FDG PET/CT.

Clin Nucl Med 2020 Jun 25. Epub 2020 Jun 25.

From the Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University; and Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China.

Primary sacral lymphoma is an unusual bone malignant tumor that poses a diagnostic challenge. Herein, we report a rare case of primary sacral lymphoma, which was initially assessed as suspicious bone metastasis. The subsequent histology and immunohistochemistry of the sacral biopsy confirmed the diagnosis of diffuse large B-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003195DOI Listing

Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome.

J Exp Med 2020 Oct;217(10)

Institute for Cancer Genetics, Columbia University, New York, NY.

In response to T cell-dependent antigens, mature B cells are stimulated to form germinal centers (GCs), the sites of B cell affinity maturation and the cell of origin (COO) of most B cell lymphomas. To explore the dynamics of GC B cell development beyond the known dark zone and light zone compartments, we performed single-cell (sc) transcriptomic analysis on human GC B cells and identified multiple functionally linked subpopulations, including the distinct precursors of memory B cells and plasma cells. The gene expression signatures associated with these GC subpopulations were effective in providing a sc-COO for ∼80% of diffuse large B cell lymphomas (DLBCLs) and identified novel prognostic subgroups of DLBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20200483DOI Listing
October 2020

Cutaneous Metastases from Testicular Diffuse Large B-cell Malignant Lymphoma and Bowen Disease: 18F-FDG PET-CT Findings.

Tokai J Exp Clin Med 2020 Jul 20;45(2):58-62. Epub 2020 Jul 20.

Department of Radiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan.

Here, we report the case of cutaneous metastases from testicular diffuse large B-cell malignant lymphoma (DLBCL) concurrent with Bowen disease evaluated with 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT). A 60-year-old male underwent orchiectomy to remove his left testicle because of DLBCL. Multiple skin lesions appeared 1 month postoperatively. Read More

View Article

Download full-text PDF

Source